| Cost‐effectiveness of magnetic resonance imaging and targeted fusion biopsy for early detection of prostate cancer CL Barnett, MS Davenport, JS Montgomery, JT Wei, JE Montie, BT Denton BJU international 122 (1), 50-58, 2018 | 64 | 2018 |
| Toward better use of bone scans among men with early-stage prostate cancer S Merdan, PR Womble, DC Miller, C Barnett, Z Ye, SM Linsell, JE Montie, ... Urology 84 (4), 793-798, 2014 | 57 | 2014 |
| Assessment of long‐term outcomes associated with urinary prostate cancer antigen 3 and TMPRSS2: ERG gene fusion at repeat biopsy S Merdan, SA Tomlins, CL Barnett, TM Morgan, JE Montie, JT Wei, ... Cancer 121 (22), 4071-4079, 2015 | 48 | 2015 |
| Clinical predictors and recommendations for staging computed tomography scan among men with prostate cancer R Risko, S Merdan, PR Womble, C Barnett, Z Ye, SM Linsell, JE Montie, ... Urology 84 (6), 1329-1334, 2014 | 39 | 2014 |
| Cost estimate of platelet transfusion in the United States for patients with chronic liver disease and associated thrombocytopenia undergoing elective procedures CL Barnett, D Mladsi, M Vredenburg, K Aggarwal Journal of Medical Economics, 2018 | 31 | 2018 |
| 18F-choline PET/mpMRI for detection of clinically significant prostate cancer: part 2. Cost-effectiveness analysis CL Barnett, MS Davenport, JS Montgomery, LP Kunju, BT Denton, M Piert Journal of Nuclear Medicine 60 (12), 1705-1712, 2019 | 17 | 2019 |
| 18F-choline PET/mpMRI for detection of clinically significant prostate cancer: part 1. Improved risk stratification for MRI-guided transrectal prostate biopsies MS Davenport, JS Montgomery, LP Kunju, J Siddiqui, PR Shankar, ... Journal of Nuclear Medicine 61 (3), 337-343, 2020 | 15 | 2020 |
| Two-Stage Biomarker Protocols for Improving the Precision of Early Detection of Prostate Cancer CL Barnett, SA Tomlins, DJ Underwood, JT Wei, TM Morgan, JE Montie, ... Medical Decision Making 37 (7), 815-826, 2017 | 14 | 2017 |
| Optimizing active surveillance strategies to balance the competing goals of early detection of grade progression and minimizing harm from biopsies CL Barnett, GB Auffenberg, Z Cheng, F Yang, J Wang, JT Wei, DC Miller, ... Cancer 124 (4), 698-705, 2018 | 12 | 2018 |
| OR practice–Data analytics for optimal detection of metastatic prostate cancer S Merdan, CL Barnett, BT Denton, JE Montie, DC Miller Operations Research 69 (3), 774-794, 2021 | 9 | 2021 |
| Cost-effectiveness of avatrombopag for the treatment of thrombocytopenia in patients with chronic liver disease D Mladsi, C Barnett, K Aggarwal, M Vredenburg, D Dieterich, R Kim ClinicoEconomics and Outcomes Research, 515-526, 2020 | 9 | 2020 |
| A framework for assessing the lifetime economic burden of congenital cytomegalovirus in the United States A Lucas, A Sinha, KB Fowler, D Mladsi, C Barnett, S Samant, L Gibson Cost Effectiveness and Resource Allocation 17, 1-10, 2019 | 8 | 2019 |
| The zero-price conundrum: exploration of scenarios where a clinically effective new drug might not be cost-effective at zero price D Mladsi, CL Barnett, G Mader, TA Russell-Smith, A Unuigbe, T Bell Value in Health 26 (3), 384-391, 2023 | 7 | 2023 |
| A disease progression model estimating the benefit of tolvaptan on time to end-stage renal disease for patients with rapidly progressing autosomal dominant polycystic kidney … G Mader, D Mladsi, M Sanon, M Purser, CL Barnett, D Oberdhan, ... BMC nephrology 23 (1), 334, 2022 | 7 | 2022 |
| Cost-effectiveness of avatrombopag for the treatment of thrombocytopenia in patients with chronic liver disease LF Allen, K Aggarwal, M Vredenburg, C Barnett, D Mladsi, R Kim Blood 134, 3454, 2019 | 4 | 2019 |
| Mortality risk in patients with autosomal dominant polycystic kidney disease D Mladsi, X Zhou, G Mader, M Sanon, J Wang, C Barnett, C Willey, ... BMC nephrology 25 (1), 56, 2024 | 1 | 2024 |
| A post hoc analysis of Projected Retained Ability Scores (PRAS) for the longitudinal assessment of cognitive functioning in patients with neuronopathic mucopolysaccharidosis II … KS Yee, C Chirila, E Davenport, D Mladsi, C Barnett, WG Kronenberger Orphanet Journal of Rare Diseases 18 (1), 343, 2023 | 1 | 2023 |
| The evolution of ICER’s review process for new medical interventions and a critical review of economic evaluations (2018-2019): how stakeholders can collaborate with ICER to … NA Ronquest, K Paret, IG Gould, CL Barnett, DM Mladsi Journal of Managed Care & Specialty Pharmacy 27 (11), 1601-1612, 2021 | 1 | 2021 |
| Value of clinical trial narrative data to estimate the costs of adverse event management: a feasibility study D Mladsi, LM Hess, CL Barnett, A Njue, YJ Huang, ZL Cui, L Bowman Journal of Medical Economics 23 (3), 213-220, 2020 | 1 | 2020 |
| PMU80 A SYSTEMATIC REVIEW OF ICER EVALUATIONS FROM 2008 TO 2018: RECENT TRENDS IN EVALUATION PROCESS AND LESSONS LEARNED NA Ronquest, IG Gould, CL Barnett, DM Mladsi Value in Health 22, S263-S264, 2019 | 1 | 2019 |
Brian DentonUniversity of Michigan在 umich.edu 的电子邮件经过验证
